Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718607 | 0.82 | ALDH1A1 (0.51) | KDM4EALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL4657999 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL2806257 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL20921007 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL21200613 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL7016542 | 0.78 | IKBKB (0.55) | KDM4EALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL2590850 | 0.78 | RECQL (0.54) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL16401095 | 0.76 | RECQL (0.50) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL11584641 | 0.74 | KDM4E (0.58) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL7015986 | 0.74 | MAPT (0.45) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| EP-3004096-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195919-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014195919-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122342-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | KDM4E 55/4885ALDH1A1 2517/4885MAPT 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.